Abstract:In this work, we designed novel peptide conjugates with plant-based iridoid and lichen-derived depside derivatives to target the wild-type EGFR (WT) and its mutants, L858R and T790M/L858R/C797S triple mutant. These mutations are often expressed in multiple cancers, particularly lung cancer. Specifically, the iridoids included 7-deoxyloganetic acid (7-DGA) and loganic acid (LG), while the depside derivative was sekikaic acid (SK). These compounds are known for their innate anticancer properties and were conjugated with two separate peptide sequences KLPGWSG (K) and YSIPKSS (Y). These sequences have been shown to target EGFR in previous phage display library screening, although the mechanism is unknown. Thus, we created the di-conjugates for dual targeting and investigated their interactions of the di-conjugates and that of the neat peptides with the kinase domain of EGFR (WT) and the two mutants using molecular docking, molecular dynamics (MD) simulations, and MM-GBSA analysis. Docking studies revealed that the (7-DGA) 2 -K showed the highest binding affinity at − 9.3 kcal/mol with the L858R mutant, while (LG) 2 -Y displayed the highest binding affinity at − 9.0 kcal/mol for the triple mutant receptor. Our results indicated that several of the conjugates interacted with crucial residues of the kinase domain, including ASP855 and THR854 (activation loop), MET793 and PRO794 (hinge region), ARG841 (catalytic loop), and LYS728 and LEU718 of the glycine-rich P-loop. Interestingly, strong hydrophobic interactions were also observed with the C-terminal tail residues, such as PHE997 and ALA1000 as well as with ARG999 for the YSIPKSS peptide and most of the conjugates. The hydroxyl group of the cyclopentane ring and the oxygen of the pyran ring of the (7-DGA) 2 -peptide conjugates contributed to binding particularly in the hinge region, while the peptide components formed an extended structure that bound well into the C-lobe. The (SK) 2 -Y di-conjugate and KLPGWSG peptide formed hydrogen bonds with the SER797 residue of the triple mutant. Overall, our results show that the (7-DGA) 2 -K, di-conjugate, the (7-DGA) 2 -Y di-conjugate, and the neat YSIPKSS demonstrated strong and stable binding with the L858R mutant and the highly resistant triple mutant EGFR, respectively. The novel designed conjugates demonstrate potential for further optimization for laboratory studies aimed at developing new therapeutics for targeting specific EGFR mutant expressing cells.

Peptide Ligand Targeted Delivery to EGFR Expressing Cancer Cells in Vitro and in Vivo

Novel Strategy Utilizing Extracellular Cysteine-Rich Domain of Membrane Receptor for Constructing D-Peptide Mediated Targeted Drug Delivery Systems: A Case Study on Fn14

Identification and Characterization of a Novel Peptide Ligand of Epidermal Growth Factor Receptor for Targeted Delivery of Therapeutics.

Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in Vivo Tumor Targeting and Imaging

EGFR/EGFRvIII Dual-Targeting Peptide-Mediated Drug Delivery for Enhanced Glioma Therapy.

HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.

EGF-coated Nano-Dendriplexes for Tumor-Targeted Nucleic Acid Deliveryin Vivo

Enhanced Transfection Efficiency And Targeted Delivery Of Self-Assembling H-R3-Dendriplexes In Egfr-Overexpressing Tumor Cells

Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells

Stable Peptides Mediated Glioma Targeting Drug Delivery

Tumor-Penetrating Peptide Fused Egfr Single-Domain Antibody Enhances Cancer Drug Penetration into 3d Multicellular Spheroids and Facilitates Effective Gastric Cancer Therapy

TNYL Peptide Functional Chitosan-G-stearate Conjugate Micelles for Tumor Specific Targeting

Liposome-Based Systemic Glioma-Targeted Drug Delivery Enabled by All-d Peptides.

Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models

Camouflaging Irgd-Egfr Anchored Human Cytotoxic T-lymphocyte Membranes to the Surface of Nanoparticles Combined with Low-Dose Irradiation: New Approach to Enhance Drug-Delivery Targeting in Gastric Cancer

A novel EGFR-targeted gene delivery system based on complexes self-assembled by EGF, DNA, and activated PAMAM dendrimers.

Biotinylated Epidermal Growth Factor Surface Modified Lipid Nanoparticles to Enhance the Targeting Efficiency in Liver Cancer Therapy

Data Allocation Strategies for Parallel Image Processing Algorithms

Developing New Peptides and Peptide-Drug Conjugates for Targeting the FGFR2 Receptor-Expressing Tumor Cells and 3D Spheroids

Targeted Delivery of Dual Anticancer Drugs Based on Self-Assembled iRGD-Modified Soluble Drug-Polymer Pattern Conjugate Nanoparticles

Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study